Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.47 |
| ▸ | LOX | P28300 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4645445 | 0.84 | CA2 (0.44) | CA2LOXCA12CA1CA9 | |
| SCHEMBL22013622 | 0.81 | LOX (0.40) | LOXL3MBTL1LOXL2KMT2AMAOA | |
| SCHEMBL10167828 | 0.81 | LOX (0.59) | CA2LOXLOXL2MAOA | |
| SCHEMBL18643569 | 0.81 | LOX (0.59) | LOXL3MBTL1LOXL2KMT2AMAOA | |
| SCHEMBL8632622 | 0.80 | CA2 (0.49) | CA2LOX | |
| SCHEMBL2010210 | 0.79 | CA2 (0.56) | CA2LOXCA12CA1CA9 | |
| SCHEMBL3005886 | 0.79 | L3MBTL1 (0.43) | LOXL3MBTL1LOXL2KMT2AMAOA | |
| SCHEMBL38666703 | 0.79 | CA2 (0.47) | CA2LOXCA12CA1CA9 | |
| SCHEMBL2117188 | 0.79 | L3MBTL1 (0.43) | LOXL3MBTL1LOXL2KMT2AMAOA | |
| SCHEMBL25034033 | 0.79 | CA2 (0.52) | CA2LOXCA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100197657-A1 | 2-ARYL OR HETEROARYL INDOLE DERIVATIVES | CHANG RONALD K | 2010-08-05 | — | — | US | disclosed |
| CN-1863789-B | Substituted isoquinolinones | PORTOLA PHARM INC | 2010-06-09 | — | — | CN | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| EP-1667989-A4 | SUBSTITUTED ISOQUINOLINONES | PORTOLA PHARM INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| EP-1667989-A1 | SUBSTITUTED ISOQUINOLINONES | Portola Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050113399-A1 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005035520-A1 | SUBSTITUTED ISOQUINOLINONES | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| CN-1575286-A | Thiophene-amd thiazolesulfonamides as antineoplastic agents | LILLY CO ELI (US) | 2005-02-02 | — | — | CN | disclosed |
| US-20040198784-A1 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | GROSSMAN CORA SUE (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1442030-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003035629-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2003-05-01 | — | — | WO | disclosed |
| US-5302724-A | Thiophenesulfonylureas; anticarcinogenic agents | ELI LILLY AND COMPANY (US) | 1994-04-12 | — | — | US | disclosed |
| CN-1058401-A | Anti-tumor compositions and methods of treatment | LILLY CO ELI (US) | 1992-02-05 | — | — | CN | disclosed |
| EP-0467613-A1 | Antitumor compositions and methods of treatment | ELI LILLY AND COMPANY (US) | 1992-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113399-A1 | Substituted isoquinolinones | PFKP, MPL, TBXA2R | CA2 4801/4885LOX 3815/4885L3MBTL1 2973/4885 |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | CA2 236/4885LOX 1017/4885L3MBTL1 4042/4885 |
| US-20100197657-A1 | 2-ARYL OR HETEROARYL INDOLE DERIVATIVES | ASIC1, ASIC3, TRPV1 | CA2 46/4885LOX 2942/4885L3MBTL1 4206/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | CA2 196/4885LOX 1178/4885L3MBTL1 4566/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | CA2 196/4885LOX 1178/4885L3MBTL1 4566/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CA2 196/4885LOX 1178/4885L3MBTL1 4566/4885 |
| US-20040198784-A1 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | ALDH1A2, MGMT, NR2E3 | CA2 2965/4885LOX 4603/4885L3MBTL1 4308/4885 |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | CA2 269/4885LOX 927/4885L3MBTL1 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.